Regeneron Reports Mixed Results in Ovarian Cancer Therapy Trial
Regeneron Pharmaceuticals (REGN) reported initial results from its Phase 1/2 trial of ubamatamab, an experimental therapy for ovarian cancer. Despite early gains following a collaboration expansion with Sanofi (SNY), Regeneron's stock declined in the afternoon as investors reacted to the mixed data. The company partnered with Sanofi earlier this year to expand research and development efforts across multiple therapeutic areas. However, the recent trial results did not meet all expectations, leading to investor uncertainty about ubamatamab’s potential for further clinical advancement or commercial viability. Market sentiment was affected as investors weighed the implications of these findings on Regeneron's pipeline progress in oncology.
Topics: biotech pharmaceuticals Regeneron Pharmaceuticals ubamatamab